162 related articles for article (PubMed ID: 17163240)
1. Linguistic adaptation and validation of the Spanish version of the Benign Prostatic Hyperplasia-Patient Impact Measure (BPH-PIM).
Llorente C; Ruiz M; Rejas Gutiérrez J; Esteban M; Villasante F; Hareendran A
Clin Drug Investig; 2006; 26(2):103-12. PubMed ID: 17163240
[TBL] [Abstract][Full Text] [Related]
2. Use of the International Prostate Symptom Score (IPSS) in Chinese male patients with benign prostatic hyperplasia.
Wong CK; Choi EP; Chan SW; Tsu JH; Fan CW; Chu PS; Cheung FK; Ma WK; Mah ISF; Yip SK; Hou SS; So HS; Lam CK
Aging Male; 2017 Dec; 20(4):241-249. PubMed ID: 28787255
[TBL] [Abstract][Full Text] [Related]
3. Validation of a harmonized Spanish version of the IPSS: evidence of equivalence with the original American scale. International Prostate Symptom Score.
Badía X; García-Losa M; Dal-Ré R; Carballido J; Serra M
Urology; 1998 Oct; 52(4):614-20. PubMed ID: 9763080
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a quality-of-life scale for Chinese patients with benign prostatic hyperplasia.
Shi J; Sun Z; Cai T; Yang L
BJU Int; 2004 Oct; 94(6):837-44. PubMed ID: 15476519
[TBL] [Abstract][Full Text] [Related]
5. Reproducibility and clinical and concurrent validity of the MSF-4: a four-item male sexual function questionnaire for patients with benign prostatic hyperplasia.
Marquis P; Marrel A
Value Health; 2001; 4(4):335-43. PubMed ID: 11705301
[TBL] [Abstract][Full Text] [Related]
6. Validation of the Patient Perception of Intensity of Urgency Scale in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.
Mathias SD; Crosby RD; Nazir J; Klaver M; Drogendijk T; Hakimi Z; Odeyemi IA
Value Health; 2014 Dec; 17(8):823-9. PubMed ID: 25498777
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of an Arabic version of the International Prostate Symptom Score.
Hammad FT; Kaya MA
BJU Int; 2010 May; 105(10):1434-8. PubMed ID: 19863520
[TBL] [Abstract][Full Text] [Related]
8. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
Gratzke P; Kirby RS
Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491
[TBL] [Abstract][Full Text] [Related]
9. Simplified Chinese version of the international prostate symptom score and the benign prostatic hyperplasia impact index: cross-cultural adaptation, reliability, and validity for patients with benign prostatic hyperplasia.
Dun RL; Mao JM; Yu C; Zhang Q; Hu XH; Zhu WJ; Qi GC; Peng Y
Prostate Int; 2022 Sep; 10(3):162-168. PubMed ID: 36225281
[TBL] [Abstract][Full Text] [Related]
10. The psychometric validation of a US English satisfaction measure for patients with benign prostatic hyperplasia and lower urinary tract symptoms.
Black L; Grove A; Morrill B
Health Qual Life Outcomes; 2009 Jun; 7():55. PubMed ID: 19545384
[TBL] [Abstract][Full Text] [Related]
11. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia.
Andersen M; Dahlstrand C; Høye K
Eur Urol; 2000 Oct; 38(4):400-9. PubMed ID: 11025377
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of an audit instrument: the Prostate Outcomes Questionnaire.
Lamping DL; Rowe P; Black N; Lessof L
Br J Urol; 1998 Jul; 82(1):49-62. PubMed ID: 9698662
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey.
Suzuki H; Yano M; Awa Y; Nakatsu H; Egoshi K; Mikami K; Ota S; Okano T; Hamano S; Ohki T; Furuya Y; Ichikawa T
Int J Urol; 2006 Sep; 13(9):1202-6. PubMed ID: 16984553
[TBL] [Abstract][Full Text] [Related]
14. Cultural adaptation and validation of the Pelvic Floor Distress Inventory short form (PFDI-20) and Pelvic Floor Impact Questionnaire short form (PFIQ-7) Spanish versions.
Sánchez-Sánchez B; Torres-Lacomba M; Yuste-Sánchez MJ; Navarro-Brazález B; Pacheco-da-Costa S; Gutiérrez-Ortega C; Zapico-Goñi Á
Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):281-5. PubMed ID: 23891390
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of the BSP-BPH (Bononian Satisfaction Profile--Benign Prostatic Hyperplasia) a "disease-specific" questionnaire for the evaluation of health related quality of life in patients with benign prostatic hyperplasia.
Bertaccini A; Martinelli A; Ceccarelli R; Palmieri F; Vitullo G; Urbinati M; Marchiori D; Costal F; Martorana G
Arch Ital Urol Androl; 2004 Sep; 76(3):103-9. PubMed ID: 15568297
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of psychometric properties of Japanese version of international prostate symptom score and BPH impact index].
Homma Y; Tsukamoto T; Yasuda K; Ozono S; Yoshida M; Yamaguchi T
Nihon Hinyokika Gakkai Zasshi; 2003 Jul; 94(5):560-9. PubMed ID: 12910932
[TBL] [Abstract][Full Text] [Related]
17. Effect of tamsulosin hydrochloride on lower urinary tract symptoms and quality of life in patients with benign prostatic hyperplasia. Evaluation using bother score.
Yoshida M; Sugiyama Y; Masunaga K; Maeda Y; Satoji Y; Nagata T; Inadome A
Drugs Today (Barc); 2007 Jun; 43 Suppl B():1-7. PubMed ID: 17612712
[TBL] [Abstract][Full Text] [Related]
18. Controlled-release doxazosin in the treatment of benign prostatic hyperplasia.
Hernandez C; Duran R; Jara J; Castaño I; Moralejo M
Prostate Cancer Prostatic Dis; 2005; 8(4):375-80. PubMed ID: 16264771
[TBL] [Abstract][Full Text] [Related]
19. Comparative rapid onset of efficacy between doxazosin gastrointestinal therapeutic system and tamsulosin in patients with lower urinary tract symptoms from benign prostatic hyperplasia: a multicentre, prospective, randomised study.
Chung MS; Lee SH; Park KK; Yoo SJ; Chung BH
Int J Clin Pract; 2011 Nov; 65(11):1193-9. PubMed ID: 21995695
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of the doxazosin gastrointestinal therapeutic system for the treatment of benign prostate hyperplasia.
Sun GH; Tsui KH; Wu TT; Chang CH; Cheng CL; Schou M
Kaohsiung J Med Sci; 2010 Oct; 26(10):532-9. PubMed ID: 20950778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
